A Clinical Study to Evaluate the Safety and Efficacy of ESO-T01 in Treating Relapsed/Refractory Multiple Myeloma.
- Status
- SUSPENDED
- Phase
- EARLY_PHASE1
Clinical Trials Related to Multiple Myeloma
Related studies linked through entity extraction aliases.
Characteristics and Clinical Significance of Gut Microbiota in Patients With Monoclonal Gammopathy
- Status
- RECRUITING
- Phase
- N/A
A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
- Status
- RECRUITING
- Phase
- PHASE3
Comparison Between Whole Body DWI and FDG PET/CT in Patients with Simptomatic Multiple Myeloma
- Status
- RECRUITING
- Phase
- N/A
CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study
- Status
- RECRUITING
- Phase
- N/A
A Study of OL-101 Injection in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
- Status
- RECRUITING
- Phase
- PHASE1
64Cu-LLP2A for Imaging Hematologic Malignancies
- Status
- RECRUITING
- Phase
- EARLY_PHASE1
Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)
- Status
- RECRUITING
- Phase
- NA
Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function
- Status
- RECRUITING
- Phase
- PHASE1
Study of ODX (OsteoDex) in Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
The Burden of Multiple Myeloma on Patients and Caregivers Quality of Life: a Canadian Real-World Study
- Status
- COMPLETED
- Phase
- N/A
Allogeneic Anti-BCMA/GPRC5D Bispecific CAR-NK Cells (ACT-001) in Patients With Relapsed or Refractorymultiple Myeloma
- Status
- NOT_YET_RECRUITING
- Phase
- NA
A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma as Compared With Standard of Care Therapies
- Status
- COMPLETED
- Phase
- N/A
Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan
- Status
- RECRUITING
- Phase
- PHASE3
Korean Post Marketing Surveillance for ELREXFIO (Elranatamab).
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE2
Aspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
External Beam Radiation Therapy in Combination With Talquetamab for the Treatment of Multiple Myeloma Patients With Extramedullary Disease
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2